Cost-Effectiveness of Empagliflozin in Combination with Standard Care versus Standard Care Only in the Treatment of Heart Failure Patients in Finland

PURPOSE: Sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin has recently been shown to improve the outcomes of heart failure (HF) patients regardless of patient’s left ventricular ejection fraction by reducing the combined risk of cardiovascular death or hospitalization for worsening HF....

Descripción completa

Detalles Bibliográficos
Autores principales: Hallinen, Taru, Kivelä, Santtu, Soini, Erkki, Harjola, Veli-Pekka, Pesonen, Mari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9831000/
https://www.ncbi.nlm.nih.gov/pubmed/36636485
http://dx.doi.org/10.2147/CEOR.S391455

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9831000/
https://www.ncbi.nlm.nih.gov/pubmed/36636485
http://dx.doi.org/10.2147/CEOR.S391455

Ejemplares similares